{
    "2018-05-07": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novo Nordisk Fights Payer Pressure With New Meds",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "payer pressure",
                        "new meds"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio?",
                "features": {
                    "keywords": [
                        "Novo Nordisk A/S",
                        "NYSE:NVO",
                        "PE Ratio",
                        "buy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}